Lv54
1120 积分 2025-03-22 加入
CAR T-cell therapy “Living drugs” in systemic lupus erythematosus
1天前
求助中
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review
5天前
已完结
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
5天前
已完结
Enhancing CAR-NK cell efficacy in solid tumours
6天前
已完结
Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE)
7天前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
8天前
已完结
Roads and detours for CAR T cell therapy in autoimmune diseases
8天前
已完结
Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries
8天前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
13天前
已完结
Immune-mediated side effects of cancer immunotherapies
15天前
已完结
皖公网安备34019202002308
